Skip to content

A Clinical Clinical Observation of CO2 Fractional Laser in Female Vaginal Repair

A Clinical Clinical Observation of CO2 Fractional Laser in Female Vaginal Repair: A Non-randomized, Open, Inter-group and Self-controlled Trial Before and After Treatment

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04492176
Enrollment
40
Registered
2020-07-30
Start date
2019-08-01
Completion date
2020-10-30
Last updated
2021-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaginal Atrophy

Keywords

Vaginal atrophy, Vaginal relaxation, stress urinary incontinence, CO2 fractional laser

Brief summary

1. Vaginal atrophy is the most common indication in the treatment of vaginal rejuvenation. Its main manifestation is vaginal relaxation syndrome, which may be the early symptom of female pelvic floor dysfunction. It is a common gynecological physiological change in women. Its clinical manifestations include vaginal wall relaxation, decreased elasticity, poor dryness sensitivity, internal environment disorder, and so on. Vaginal exhaust, often combined with urinary incontinence, pelvic organ prolapse, chronic pelvic discomfort and other symptoms, seriously affecting patients'health and quality of sexual life. At present, there are many treatments for vaginal relaxation,vaginal constriction and laser therapy are the most effective and widely accepted treatments. Laser therapy with small trauma and short repair time has attracted much attention. 2. CO2 fractional laser (Acupulse) stimulates fibroblasts to synthesize and secrete collagen fibers, elastic fibers, reticular fibers and organic matrix through dot exfoliation and thermal stimulation, thus thickening the vaginal wall and achieving long-term vaginal tightening effect. The heat effect of CO2 laser can stimulate vasodilation, increase blood flow, increase cell oxidation and nutrients, increase mitochondrial ATP release, activate cell function, enhance vaginal mucosal secretion, enhance secretion, normalize vaginal PH and bacterial flora, and then reduce the probability of gynecological infection. 3. It has been reported that CO2 lattice laser can stimulate collagen synthesis and rearrangement. It has also been reported that CO2 lattice laser may have important clinical significance in improving the morphology and function of vaginal epithelial cells.

Detailed description

1. Vaginal atrophy is the most common indication in the treatment of vaginal rejuvenation. Its main manifestation is vaginal relaxation syndrome, which may be the early symptom of female pelvic floor dysfunction. It is a common gynecological physiological change in women. Its clinical manifestations include vaginal wall relaxation, decreased elasticity, poor dryness sensitivity, internal environment disorder, and so on. Vaginal exhaust, often combined with urinary incontinence, pelvic organ prolapse, chronic pelvic discomfort and other symptoms, seriously affecting patients'health and quality of sexual life. At present, there are many treatments for vaginal relaxation,vaginal constriction and laser therapy are the most effective and widely accepted treatments. It should be noted that patients with vaginal constriction need anti-scar training for a long time after operation to prevent the effect of vaginal entrance narrowing and vaginal wall scar formation on the quality of life of patients during the repair period. Therefore, laser therapy with small trauma and short repair time has attracted much attention. 2. CO2 fractional laser (Acupulse) stimulates fibroblasts to synthesize and secrete collagen fibers, elastic fibers, reticular fibers and organic matrix through dot exfoliation and thermal stimulation, thus thickening the vaginal wall and achieving long-term vaginal tightening effect. The heat effect of CO2 laser can stimulate vasodilation, increase blood flow, increase cell oxidation and nutrients, increase mitochondrial ATP release, activate cell function, enhance vaginal mucosal secretion, enhance secretion, normalize vaginal Internal environment and bacterial flora, and then reduce the probability of gynecological infection. 3. It has been reported that CO2 lattice laser can stimulate collagen synthesis and rearrangement. It has also been reported that CO2 lattice laser may have important clinical significance in improving the morphology and function of vaginal epithelial cells. Our center has also passed the clinical observation ethical review of CO2 lattice laser to improve female vaginal relaxation in 2016, and completed the clinical trial at the end of 2017. The data further confirm that CO2 lattice laser can improve vaginal relaxation and is significantly effective for stress urinary incontinence.

Interventions

DEVICECO2 fractional laser(ACUPULSE,Lumenis)

gradually withdrawn from inside to outside of vaginal. with Acupulse Femtouch mode therapy ( hexagonal spot , 10-12.5m J/cm2 , density 5-15%) ,once a month for a total of 3 times

Sponsors

Xijing Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
25 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Married women aged 25-75 with improvement needs; * Agree to participate in the experiment and sign the informed consent. * Female sexual dysfunction patients; * No other external treatment was performed before treatment at the lesion site. * VTI instrument was used for intravaginal pressure test to assess urinary incontinence and vaginal senility caused by chronic muscle dysfunction

Exclusion criteria

* Pregnant or lactating women; * suffering from severe mental disorders, psychological disorders, personality disorders and major organ dysfunction; * Patients with severe hematological diseases, Sjogren's syndrome, systemic and therapeutic site infections; * Patients who took high doses of anticoagulants or hormones within one month; * Laser allergy history, photosensitive reactor; * Women with acute vaginitis or cervicitis; * Pap smear positive patients; * Female HIV (HIV), HPV (papillary virus), HSV (herpes simplex virus) positive patients; * Use of antifungal drugs, vaginal administration, vaginal irrigation and female sprays in the past 30 days * The condition of the visual field of laser surgery affected by ulceration and infection of the skin lesion * Those who have undergone vaginal tightening surgery with other substances or means

Design outcomes

Primary

MeasureTime frameDescription
histopathological biopsyChanges before and 1month after treatment5 cases were randomly selected for histopathological biopsy
pelvic floor magnetic resonance MRI plainChanges from preoperative to 1 year after initial treatmentMeasure tissue structures in the pelvis
scantransvaginal ultrasoundChanges from preoperative to 1 year after initial treatmentMeasure the structures of the vagina
female sexual function FSFI score(Female Sexual Function Index )Changes from preoperative to 1 year after initial treatmentQuestionnaire content involving sexual activity, intercourse, sexual stimulation, sexual desire or sexual interest, sexual excitement or sexual arousal, evaluation of female sexual function, questionnaire score ≤ 26.55 is considered female sexual dysfunction
urinary incontinence questionnaire short form assessmentChanges from preoperative to 1 year after initial treatmentEvaluate urinary incontinence questionnaire short form assessment
VHIS score in vaginal environmentChanges from preoperative to 1 year after initial treatmentComprehensive evaluation of vaginal status by vulvar status, internal PH value, vaginal elasticity, guided endocrine secretion, and vaginal moistness
vaginal pressure VTI data detectionChanges from preoperative to 1 year after initial treatmentEvaluate vaginal pressure by VTI data detection

Secondary

MeasureTime frameDescription
VAS Pain Assessment(Immediately after Treatment)3 monthsVAS pain scoring criteria (0-10 points): 0 points: no pain; less than 3 points: mild pain, can tolerate; 4 points 1-6 points: patients with pain and affect sleep, can still tolerate; 7 points-10 points : The patient has increasing pain, and the pain is intolerable
patient satisfaction assessmentChanges from preoperative to 1 year after initial treatmentPatient satisfaction: Very satisfied, satisfied, average, dissatisfied, very dissatisfied

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026